Passez à l'illimité avec Magzter GOLD
Obtenez un accès illimité à plus de 9 000 magazines, journaux et articles Premium pour seulement
Essayer OR - Gratuit
Does US cancer drug nod make Cipla attractive?
Mint New Delhi
|April 18, 2025
Cipla, which makes HIV, respiratory and cancer drugs, is targeting North America with generic launches
Cipla Ltd's shares have surged 6% since last week when it announced the final approval from the US Food and Drug Administration for its generic version of Bristol Myers Squibb's Abraxane, a cancer drug. Does the approval to sell the much-awaited product in the US make Cipla a compelling buy, especially when Trump's tariffs loom?
"One product approval by itself doesn't suddenly make a company more attractive," said Prashant Nair, lead analyst for pharma and healthcare at Ambit Capital. "Earlier-than-expected approval for Abraxane is positive, but tariffs will have a bearing on Cipla."
Cette histoire est tirée de l'édition April 18, 2025 de Mint New Delhi.
Abonnez-vous à Magzter GOLD pour accéder à des milliers d'histoires premium sélectionnées et à plus de 9 000 magazines et journaux.
Déjà abonné ? Se connecter
PLUS D'HISTOIRES DE Mint New Delhi
Mint New Delhi
Sebi now trains sights on commodity derivatives
Following clampdown on equity derivatives after studies revealed steep retail losses, the stock market regulator is turning its attention to the commodity derivatives segment (CDS).
2 mins
November 28, 2025
Mint New Delhi
Refiners, SCI tap Korean giants for local shipyard
Indian Oil, Bharat Petroleum and Hindustan Petroleum are part of the discussions
4 mins
November 28, 2025
Mint New Delhi
360 One, Steadview, others to invest in Wakefit ahead of IPO
A clutch of firms, including 360 One, Steadview Capital, WhiteOak Capital and Info Edge, is expected to invest in home-furnishings brand Wakefit Innovations Ltd just ahead of its initial public offering (IPO) next month, three people familiar with the matter said.
3 mins
November 28, 2025
Mint New Delhi
Would you like to be interviewed by an AI bot instead?
I don't think I want to be interviewed by a human again,\" said a 58-year-old chartered accountant who recently had an interview with a multinational company.
3 mins
November 28, 2025
Mint New Delhi
India, UAE review trade agreement to ease market access
Officials of India and the United Arab Emirates (UAE) met on Thursday to review how the Comprehensive Economic Partnership Agreement (CEPA) is working, and remove frictions that may be impeding trade between the two nations.
1 mins
November 28, 2025
Mint New Delhi
It's a multi-horse Street race now as Smids muscle in
For years, India’s stock market ran on the shoulders of a few giants. Not anymore.
3 mins
November 28, 2025
Mint New Delhi
The curious case of LIC's voting on RIL, Adani resolutions
Life Insurance Corp. of India Ltd, or LIC, consistently approved or never opposed resolutions proposed before shareholders of Reliance Industries Ltd (RIL) or any Adani Group company since 1 April 2022, even as it rejected several similar proposals at other large companies, some even part of other conglomerates, a Mint review of about 9,000 voting decisions by the government-run insurer showed.
8 mins
November 28, 2025
Mint New Delhi
Investors expect AI use to soar. That's not happening
On November 20th American statisticians released the results of a survey. Buried in the data is a trend with implications for trillions of dollars of spending.
4 mins
November 28, 2025
Mint New Delhi
CANADA'S STARTUP VISA: PUTTING LIVES ON HOLD
Legal uncertainty has left entrepreneurs stuck despite building businesses and putting down roots
8 mins
November 28, 2025
Mint New Delhi
Gupta pilfered from fraud, Trafigura says
Commodity trader Trafigura's lawyers accused Indian businessman Prateek Gupta on Thursday of siphoning off funds from an alleged $600 million metals fraud to prop up his struggling business empire.
1 min
November 28, 2025
Listen
Translate
Change font size